Market Research

Global Janus Kinase (JAK) Inhibitors Market Size and Forecast 2024-2033|Pfizer Inc., Merck & Co. Inc., AbbVie Inc., Novartis AG, Sanofi SA

The Janus Kinase (JAK) Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions – Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Janus Kinase (JAK) Inhibitors Market:

https://www.thebusinessresearchcompany.com/report/janus-kinase-jak-inhibitors-global-market-report

According to The Business Research Company’s Janus Kinase (JAK) Inhibitors Global Market Report 2024, The janus kinase (jak) inhibitors market size has grown rapidly in recent years. It will grow from $17.29 billion in 2023 to $20.41 billion in 2024 at a compound annual growth rate (CAGR) of 18.1%.  The  growth in the historic period can be attributed to recognition of the role of jak-stat signaling pathway in diseases, increased prevalence of autoimmune disorders, unmet medical needs in rheumatology and dermatology, development of targeted therapies for inflammatory conditions, improvement in diagnostic capabilities for autoimmune diseases.

The janus kinase (jak) inhibitors market size is expected to see rapid growth in the next few years. It will grow to $39.92 billion in 2028 at a compound annual growth rate (CAGR) of 18.3%.  The growth in the forecast period can be attributed to growth of biopharmaceutical research and development, regulatory approvals for jak inhibitors in specific indications, expansion of clinical trials for jak inhibitor drugs, advances in personalized and precision medicine, adoption of jak inhibitors in combination therapies, integration of digital health technologies in autoimmune care. Major trends in the forecast period include focus on developing novel selective jak inhibitors for improved safety profiles, development of jak inhibitors with extended-release formulations, integration of artificial intelligence in jak inhibitor drug discovery, exploration of jak inhibitors in novel drug delivery systems, collaboration between pharmaceutical companies and research institutions.

The increase in instances of autoimmune diseases is expected to propel the growth of the Janus kinase (JAK) inhibitors market. Autoimmune diseases are a broad group of disorders characterized by an abnormal immune response in which the immune system mistakenly attacks and damages healthy cells, tissues, and organs. Janus Kinase (JAK) inhibitors provide therapeutic benefits for autoimmune diseases by modulating the immune system, reducing inflammation, and alleviating symptoms such as rheumatoid arthritis. For instance, in December 2022, according to the National Psoriasis Foundation, a US-based non-profit organization serving people with Psoriasis and psoriatic arthritis, Psoriasis affected more than 8 million people in America and 125 million individuals worldwide, or 2 to 3% of the population. Furthermore, in September 2022, according to the Centers for Disease Control and Prevention, a US-based national public health agency, Diabetes was diagnosed in 28.7 million people of all ages, or 8.7% of the US population, and 5.7% of all US individuals with confirmed Diabetes—or 1.6 million people aged 20 and older—reported having type 1 diabetes and requiring insulin. Therefore, the increase in instances of autoimmune diseases is driving the growth of the Janus kinase (JAK) inhibitors market.

Get A Free Sample Of The Report (Includes Graphs And Tables):

https://www.thebusinessresearchcompany.com/sample.aspx?id=12524&type=smp

The janus kinase (jak) inhibitors market covered in this report is segmented –

1) By Inhibitors Type: Ruxolitinib, Tofacitinib, Oclacitinib, Baricitinib, Peficitinib, Other Inhibitor Types

2) By Mode Of Administration: Injectable, Oral, Other Modes Of Administration

3) By Distribution Channel: Hospital pharmacies, Retail pharmacies, Online pharmacies

4) By Application: Autoimmune Disorders, Oncology, Inflammatory Disorders, Metabolic Disorders

Product innovation is a key trend gaining popularity in the Janus kinase (JAK) inhibitors market. Major companies operating in the Janus kinase (JAK) inhibitors market are focused on innovating technologically advanced solutions to sustain their position in the market. For instance, in May 2022, Eli Lilly and Company, a US-based pharmaceutical company, and Incyte, a Switzerland-based biopharmaceutical company, announced the approval of OLUMIANT (baricitinib) by the U.S. Food and Drug Administration (FDA). It is the first and only JAK inhibitor FDA-approved for treating COVID-19 in some hospitalized individuals who need varying levels of oxygen assistance. OLUMIANT is approved for treating adult hospital patients with extracorporeal membrane oxygenation (ECMO), non-invasive or invasive mechanical breathing, or COVID-19 disease 2019 (COVID-19).

The janus kinase (jak) inhibitors market report table of contents includes:

1. Executive Summary

2. Janus Kinase (JAK) Inhibitors Market Characteristics

3. Janus Kinase (JAK) Inhibitors Market Trends And Strategies

4. Janus Kinase (JAK) Inhibitors Market – Macro Economic Scenario

5. Global Janus Kinase (JAK) Inhibitors Market Size and Growth

.

.

.

26. South America Janus Kinase (JAK) Inhibitors Market

27. Brazil Janus Kinase (JAK) Inhibitors Market

28. Middle East Janus Kinase (JAK) Inhibitors Market

29. Africa Janus Kinase (JAK) Inhibitors Market

30. Janus Kinase (JAK) Inhibitors Market Competitive Landscape And Company Profiles

Top Major Players:

  • Pfizer Inc
  • Merck & Co. Inc
  • AbbVie Inc
  • Novartis AG
  • Sanofi SA

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Good PR News

Recent Posts

Warmer Display Cases Market Segments, Growth, Key Drivers And Forecast To 2033

The warmer display cases global market report 2024 from The Business Research Company provides comprehensive…

43 mins ago

Veterinary Renal Disease Market Scope, Drivers And Overview By 2033

The veterinary renal disease global market report 2024from The Business Research Company provides comprehensive market…

47 mins ago

Spring Loaded Industrial Cable Reels Market Size, Share, Trends And Forecast 2024-2033

The spring loaded industrial cable reels global market report 2024 from The Business Research Company…

51 mins ago

Secure Data Destruction Market Size, Share, Trends, Growth And Industry Forecast 2024-2033

The secure data destruction global market report 2024 from The Business Research Company provides comprehensive…

55 mins ago

QR Code Payments Market Size, Industry Analysis, Outlook 2033

The qr code payments global market report 2024 from The Business Research Company provides comprehensive…

60 mins ago

Plastic Additives Market Overview, Trends And Forecast 2024-2033

The plastic additives global market report 2024 from The Business Research Company provides comprehensive market…

1 hour ago